Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020

As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs). The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immu...

Full description

Saved in:
Bibliographic Details
Published in:China CDC weekly 2024-12, Vol.6 (50), p.1331-1336
Main Authors: Gao, Linying, Cui, Xufeng, Mo, Xinyuan, Men, Zhaoyue, Xu, Xiuyang, Yao, Tian, Wang, Jianmin, Liu, Hongting, Guo, Hongping, Chai, Guowei, Liu, Liming, Wang, Fuzhen, Liang, Xiaofeng, Wang, Suping, Feng, Yongliang
Format: Article
Language:English
Subjects:
Preplanned Studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs). The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL. The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.
ISSN:2096-7071
2096-7071
DOI:10.46234/ccdcw2024.264